Positive 12-Month Data for NervAlign Nerve Guide Matrix

• 12-month preclinical data shows strong nerve regeneration and function recovery in sheep
• All treated animals showed similar walking ability to controls
• Nerve testing demonstrated return of sensory and motor nerve signals

ReNerve Limited (ASX:RNV) reports positive interim 12-month results from its ongoing preclinical study of the NervAlign Nerve Guide Matrix (NGM). The study evaluated a 4cm section of the NGM implanted in a sheep peripheral nerve model, compared with an autologous nerve graft control. The positive data highlight the utility and value of the ReNerve NGM in a clinically challenging setting, as defects longer than 3cm are generally considered critical. The study included six implants in total, with three NGM implants and three autologous nerve grafts. The NGM implants replicate a typical nerve replacement. Autologous nerve grafting, where a patient's own nerve is used to repair a damaged nerve, is a commonly used surgical approach for repairing larger nerve gaps. The study is assessing whether NGM can support nerve regeneration across a 4cm gap without requiring a donor nerve. All animals recovered well following surgery and were walking freely within hours. At 12 months, animals treated with NGM showed similar gait to animals treated with an autologous nerve graft and animals that had not undergone the nerve intervention. Nerve conduction testing at 12 months detected both sensory and motor nerve signals in animals treated with NGM, demonstrating that nerve signals were able to travel across the repaired area. Similar nerve conduction results were observed in animals treated with autologous nerve grafts.